Research

To begin, the designation of END products as “tobacco products” rather than “medical products” meant manufacturers did not have to meet pharmaceutical safety standards.

Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.

The COVID-19 pandemic has imposed significant and far-reaching health and economic costs. This white paper models and monetizes the health-related benefits of two hypothetical treatments administered either before or after hospitalization; both generate substantial value.

Christen Linke Young explains the dangers of junk insurance.

A review of 145 opioid policy evaluation studies found that greater adoption of more rigorous study designs and statistical methods is warranted.

Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.

States have implemented multiple strategies to enhance the capacity and quality of treatment services for opioid use disorder.

This study provides the first evidence to our knowledge that near‐universal access to Medicare at age 65 is associated with improvements in population‐level cancer mortality.

Out‐of‐network air ambulance bills are a type of surprise medical bill and are driven by many of the same market failures behind other surprise medical bills.

The study analyzes Medicare coverage delays among the uninsured and their effect on long-term peritoneal dialysis use.